Warning! GuruFocus detected
1 Medium warning sign
with 1734.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Sinphar Pharmaceutical Co Ltd
ISIN : TW0001734002
Description
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.62 | |||||
| Equity-to-Asset | 0.52 | |||||
| Debt-to-Equity | 0.58 | |||||
| Debt-to-EBITDA | 3.17 | |||||
| Interest Coverage | 8 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.23 | |||||
| Beneish M-Score | -2.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.9 | |||||
| 3-Year EBITDA Growth Rate | 76.3 | |||||
| 3-Year Book Growth Rate | 6.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.91 | |||||
| 9-Day RSI | 65.9 | |||||
| 14-Day RSI | 62.94 | |||||
| 3-1 Month Momentum % | 6.76 | |||||
| 6-1 Month Momentum % | -3.81 | |||||
| 12-1 Month Momentum % | -2.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.84 | |||||
| Quick Ratio | 1.34 | |||||
| Cash Ratio | 0.83 | |||||
| Days Inventory | 152.51 | |||||
| Days Sales Outstanding | 55.58 | |||||
| Days Payable | 48.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.13 | |||||
| Dividend Payout Ratio | 0.59 | |||||
| 3-Year Dividend Growth Rate | 75.5 | |||||
| Forward Dividend Yield % | 3.13 | |||||
| 5-Year Yield-on-Cost % | 34.07 | |||||
| Shareholder Yield % | 2.31 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 39.26 | |||||
| Operating Margin % | 9.33 | |||||
| Net Margin % | 9.67 | |||||
| FCF Margin % | 10.69 | |||||
| ROE % | 9.59 | |||||
| ROA % | 4.83 | |||||
| ROIC % | 6 | |||||
| 3-Year ROIIC % | 179.71 | |||||
| ROC (Joel Greenblatt) % | 8.81 | |||||
| ROCE % | 6.8 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.03 | |||||
| Forward PE Ratio | 18.08 | |||||
| PE Ratio without NRI | 19.02 | |||||
| Shiller PE Ratio | 58.93 | |||||
| Price-to-Owner-Earnings | 13.98 | |||||
| PEG Ratio | 0.48 | |||||
| PS Ratio | 1.83 | |||||
| PB Ratio | 1.76 | |||||
| Price-to-Tangible-Book | 1.82 | |||||
| Price-to-Free-Cash-Flow | 17.32 | |||||
| Price-to-Operating-Cash-Flow | 9.81 | |||||
| EV-to-EBIT | 19.79 | |||||
| EV-to-EBITDA | 11.33 | |||||
| EV-to-Revenue | 2.15 | |||||
| EV-to-FCF | 20 | |||||
| Price-to-GF-Value | 0.96 | |||||
| Price-to-Projected-FCF | 1.96 | |||||
| Price-to-Median-PS-Value | 0.98 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.76 | |||||
| Price-to-Graham-Number | 1.24 | |||||
| Earnings Yield (Greenblatt) % | 5.05 | |||||
| FCF Yield % | 5.8 | |||||
| Forward Rate of Return (Yacktman) % | 21.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sinphar Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 3,150.628 | ||
| EPS (TTM) (NT$) | 1.682 | ||
| Beta | -0.03 | ||
| 3-Year Sharpe Ratio | 0.18 | ||
| 3-Year Sortino Ratio | 0.29 | ||
| Volatility % | 12.74 | ||
| 14-Day RSI | 62.94 | ||
| 14-Day ATR (NT$) | 0.347106 | ||
| 20-Day SMA (NT$) | 31.5875 | ||
| 12-1 Month Momentum % | -2.63 | ||
| 52-Week Range (NT$) | 28.6 - 36.296296 | ||
| Shares Outstanding (Mil) | 181.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sinphar Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sinphar Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sinphar Pharmaceutical Co Ltd Frequently Asked Questions
What is Sinphar Pharmaceutical Co Ltd(TPE:1734)'s stock price today?
The current price of TPE:1734 is NT$32.00. The 52 week high of TPE:1734 is NT$36.30 and 52 week low is NT$28.60.
When is next earnings date of Sinphar Pharmaceutical Co Ltd(TPE:1734)?
The next earnings date of Sinphar Pharmaceutical Co Ltd(TPE:1734) is .
Does Sinphar Pharmaceutical Co Ltd(TPE:1734) pay dividends? If so, how much?
The Dividend Yield %  of Sinphar Pharmaceutical Co Ltd(TPE:1734) is 3.13% (As of Today), Highest Dividend Payout Ratio of Sinphar Pharmaceutical Co Ltd(TPE:1734) was 178. The lowest was 0.15. And the median was 0.89. The  Forward Dividend Yield % of Sinphar Pharmaceutical Co Ltd(TPE:1734) is 3.13%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers